Two Pfizer Vaccine Candidates Show Positive Results

September 20, 2022

Pfizer’s investigational meningococcal vaccine MenABCWY has delivered promising results in a late-stage trial in healthy participants aged 10 through 25 years old.

The vaccine candidate demonstrated noninferiority to licensed vaccines for the five meningococcal serogroups that cause the majority of invasive meningococcal disease: serogroups A, B, C, W and Y.

Another investigational vaccine from Pfizer, its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease, pneumonia and acute otitis media caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes, also showed promising results in the pediatric population. The company said a three-dose series of the vaccine is likely to help protect against all 20 vaccine serotypes.

Pfizer intends to submit a Biologics License Application to the FDA for MenABCWY in the fourth quarter of this year. The company plans on submitting the data on the 20vPnC vaccine to the European Medicines Agency later this year.

View today's stories